financetom
Business
financetom
/
Business
/
ING Comments on The Euro
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ING Comments on The Euro
Aug 15, 2024 3:38 AM

06:18 AM EDT, 08/15/2024 (MT Newswires) -- The eurozone economy doesn't have a lot to shout about at the moment, said ING.

A rebound in the Chinese economy remains elusive, wrote the bank in a note. Yet the prospect of the United States economy and interest rates converging on the lower levels in the rest of the world is proving supportive for EUR/USD.

This can be seen in the foreign exchange (FX) options market, where in the one-month tenor, the price of a euro (EUR) call option over a euro put option has turned positive for the first time since February 2022, stated ING. The bank feels EUR/USD had the legs to move to 1.12.

ING would like to keep this bias for the time being even though the prospect of European Uonion fiscal consolidation and potentially wider sovereign spreads may reappear in September.

The bank sees EUR/USD support at 1.0985/1000 and any softer US activity data could drag it up towards 1.11. While it is tempting to say that EUR/USD will remain in a 1.05-1.11 range for evermore, ING would caution that realized EUR/USD volatility has been exceptionally low over the last couple of years and that range breakout should be respected.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Hutchmed Completes Patient Enrollment in Phase 3 Study of Lung Cancer Combination Treatment
Hutchmed Completes Patient Enrollment in Phase 3 Study of Lung Cancer Combination Treatment
Aug 20, 2025
04:16 AM EDT, 08/20/2025 (MT Newswires) -- Hutchmed ( HCM ) said late Tuesday it completed patient enrollment in a phase 3 study of Orpathys and Tagrisso as a first-line combination treatment of a certain type of non-small cell lung cancer. The treatment targets patients whose tumors harbor epidermal growth factor receptor mutation and MET overexpression. The company said the...
Myriad Genetics Teams Up With Angle on Cancer Diagnostics
Myriad Genetics Teams Up With Angle on Cancer Diagnostics
Aug 20, 2025
04:09 AM EDT, 08/20/2025 (MT Newswires) -- Myriad Genetics ( MYGN ) has formed a collaboration with liquid biopsy company Angle, the latter said Wednesday. Under the collaboration, Angle's research and development team will process blood samples from cancer patients using the Parsortix system for downstream molecular analysis. The results will be compared with matched patient tissue samples using Myriad...
Futu Q2 Earnings, Revenue Rise
Futu Q2 Earnings, Revenue Rise
Aug 20, 2025
04:25 AM EDT, 08/20/2025 (MT Newswires) -- Futu ( FUTU ) reported Q2 earnings Wednesday of 18.24 Hong Kong dollars ($2.33) per diluted American depositary share, up from HK$8.66 a year earlier. A single analyst polled by FactSet expected HK$17.08. Revenue for the quarter ended June 30 was HK$5.31 billion, up from HK$3.13 billion a year earlier. Four analysts surveyed...
ATRenew Q2 Adjusted Earnings, Revenue Rise; Issues Q3 Revenue Guidance
ATRenew Q2 Adjusted Earnings, Revenue Rise; Issues Q3 Revenue Guidance
Aug 20, 2025
04:28 AM EDT, 08/20/2025 (MT Newswires) -- ATRenew ( RERE ) reported Wednesday Q2 adjusted earnings of 0.61 renminbi ($0.09) per diluted share, up from 0.48 renminbi per share a year earlier. A single analyst polled by FactSet expected 0.57 renminbi per share. Revenue for the quarter ended June 30 was 4.99 billion renminbi, up from 3.78 billion renminbi a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved